Querol-Vilaseca Marta, Sirisi Sònia, Molina-Porcel Laura, Molina Beatriu, Pegueroles Jordi, Ferrer-Raventós Paula, Nuñez-Llaves Raúl, Dols-Icardo Oriol, Balasa Mircea, Iulita Maria Florencia, Blesa Rafael, Belbin Olivia, Clarimon Jordi, Fortea Juan, Gelpi Ellen, Sánchez-Valle Raquel, Lleó Alberto
Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12781. doi: 10.1111/nan.12781. Epub 2021 Dec 7.
We report the neuropathological examination of a patient with Alzheimer's disease (AD) treated for 38 months with low doses of the BACE-1 inhibitor verubecestat. Brain examination showed small plaque size, reduced dystrophic neurites around plaques and reduced synaptic-associated Aβ compared with a group of age-matched untreated sporadic AD (SAD) cases. Our findings suggest that BACE-1 inhibition has an impact on synaptic soluble Aβ accumulation and neuritic derangement in AD.
我们报告了一名接受低剂量β-分泌酶1（BACE-1）抑制剂Verubecestat治疗38个月的阿尔茨海默病（AD）患者的神经病理学检查结果。与一组年龄匹配的未经治疗的散发性AD（SAD）病例相比，脑部检查显示斑块尺寸较小、斑块周围营养不良性神经突减少以及与突触相关的淀粉样β蛋白（Aβ）减少。我们的研究结果表明，抑制BACE-1对AD中突触可溶性Aβ积累和神经突紊乱有影响。
